Demographic and clinical characteristics of the 527 RA patients
| Per cent | Mean (SD) | ||
|---|---|---|---|
| Inclusion age, years | 57 (15) | ||
| Disease duration, months | 6.2 (3.2) | ||
| Gender | Women | 64 | |
| Ever smokers | 55 | ||
| Anti-CCP | Positive | 56 | |
| Rheumatoid factor | Positive | 60 | |
| VAS pain (0–10 cm) | 4.5 (2.4) | ||
| DAS28 | 5.23 (1.2) | ||
| CRP (mg/L) | 35 (37) | ||
| Tender joint count (28 joints) | 8 (6) | ||
| Swollen joint count (28 joints) | 11 (6) | ||
| VAS PatGA (0–10 cm) | 4.4 (2.5) | ||
| VAS PhGA (0–10 cm) | 4.8 (1.7) | ||
| HAQ (0–3) | 1.0 (0.65) | ||
| SHS (median (IQR)) | 1 (0–4.5) | ||
| Glucocorticoids | Yes | 42 | |
| DMARDS | No | 13 | |
| MTX | 40 | ||
| SAL | 34 | ||
| Other | 12 | ||
| Combination | 1 | ||
| Biologics | 0 |
Anti-CCP, antibodies to citrullinated peptides; CRP, C reactive protein; DAS28, disease activity score calculated on 28 joints; HAQ, Health Assessment Questionnaire; PatGA, patients global assessment; PhGA, physician's global assessment; MTX, methotrexate; RA, rheumatoid arthritis; SHS, Sharp van der Heijde total Score; SAL, sulfasalazine; VAS, visual analogue scale.